Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Immunome Inc.

IMNM Nasdaq Pharmaceutical Preparations Financials FY2019โ€“FY2025

Last close ยท Oct 23, 2026

$17.99

1.5%
Compare
Revenue Total sales reported in the income statement.
$6.9M
23.2% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’3,228.8%
153.5ย pts
Net income Profit after all expenses, interest and tax.
โˆ’$212M
Free cash flow Cash from operations minus capital spending.
โˆ’$201M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$2.0B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$2.54 EPS (TTM)

What Immunome Inc. does

No business description yet.

Legal name
Immunome Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Mar 3, 2026
Accession ยท CIK
0001193125-26-088172
0001472012

Revenue and margins

Immunome Inc. had $6.9M of revenue in fiscal 2025, down 23.2% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$201M in fiscal 2025, โˆ’2,890.1% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Immunome Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 49.0%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Immunome Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $49.2M$20.3M$138M$217M$653M
Current ratio 5.8x3.1x6.6x4.1x14.7x
Quick ratio 5.8x3.1x6.6x4.1x14.7x
Total assets $57.9M$24.0M$149M$240M$683M
Total liabilities $9.7M$7.4M$28.7M$59.1M$48.8M
Shareholders' equity $48.2M$16.7M$120M$181M$634M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ“ โœ• โœ• โœ“ โœ• โœ“
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โœ“ โœ• โœ• โœ“ โœ• โœ“
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โœ“ โœ“ โœ“ โœ“ โœ• โœ•
F-score โ€” / 34 / 72 / 72 / 74 / 71 / 73 / 7
Accruals ratio โˆ’16.7%โˆ’23.0%โˆ’12.7%โˆ’20.0%โˆ’115.0%โˆ’93.7%โˆ’4.7%
Altman Z'' โˆ’56.2413.693.13โˆ’19.50โˆ’0.03โˆ’7.7713.87

7 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue โˆ’$0.1M โˆ’$0.0M โˆ’$0.0M $0.0M $14.0M $9.0M $6.9M
Net interest income โˆ’$0.1M โˆ’$0.0M โˆ’$0.0M $0.0M $2.7M $12.8M $11.7M
Research and development $8.8M $7.5M $14.1M $23.3M $23.1M $130M $177M
Operating income โˆ’$10.3M โˆ’$12.3M โˆ’$25.2M โˆ’$36.9M โˆ’$110M โˆ’$306M โˆ’$224M
Interest expense $0.0M $0.0M โ€” โ€” โ€” โ€” โ€”
Income tax $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Net income โˆ’$10.4M โˆ’$17.8M โˆ’$24.7M โˆ’$36.9M โˆ’$107M โˆ’$293M โˆ’$212M
Net income to common โ€” โ€” โˆ’$24.7M โˆ’$37.5M โˆ’$107M โˆ’$293M โˆ’$212M
Diluted EPS โˆ’$9.55 โˆ’$5.26 โˆ’$2.14 โˆ’$3.09 โˆ’$5.38 โˆ’$5.00 โˆ’$2.43
Diluted shares 0.00B 0.00B 0.01B 0.01B 0.02B 0.06B 0.09B
Cash flow
Cash from operations โˆ’$9.6M โˆ’$12.1M โˆ’$18.2M โˆ’$28.7M โˆ’$7.6M โˆ’$111M โˆ’$191M
Capital expenditure $0.2M $0.6M $0.1M $0.2M $0.8M $7.2M $9.7M
Free cash flow โˆ’$9.8M โˆ’$12.7M โˆ’$18.3M โˆ’$28.9M โˆ’$8.4M โˆ’$118M โˆ’$201M
Depreciation and amortization $0.6M $0.8M $0.8M $0.4M $0.5M $1.6M $2.5M
Stock-based compensation $0.0M $0.6M $3.4M $5.3M $6.2M $15.7M $25.7M
Balance sheet
Cash and short-term investments $2.5M $39.8M $49.2M $20.3M $138M $217M $653M
Total debt โ€” $0.5M โ€” โ€” โ€” โ€” โ€”
Current assets $3.1M $42.9M $56.6M $22.6M $145M $221M $661M
Current liabilities $1.7M $3.0M $9.7M $7.3M $21.8M $54.3M $45.0M
Property and equipment, net $1.7M $1.5M $0.9M $0.7M $2.1M $10.1M $14.6M
Total assets $5.1M $44.5M $57.9M $24.0M $149M $240M $683M
Total liabilities $1.8M $3.2M $9.7M $7.4M $28.7M $59.1M $48.8M
Shareholders' equity โˆ’$35.6M $41.3M $48.2M $16.7M $120M $181M $634M
Margins
Operating margin 10,779.2% 32,265.8% 252,040.0% โˆ’738,020.0% โˆ’781.4% โˆ’3,382.4% โˆ’3,228.8%
EBITDA margin 10,138.5% 30,278.9% 244,490.0% โˆ’729,580.0% โˆ’778.1% โˆ’3,365.0% โˆ’3,193.3%
Net margin 10,879.2% 46,939.5% 247,110.0% โˆ’737,920.0% โˆ’761.9% โˆ’3,240.4% โˆ’3,060.0%
FCF margin 10,242.7% 33,473.7% 183,050.0% โˆ’578,760.0% โˆ’59.9% โˆ’1,304.8% โˆ’2,890.1%
Net interest share of revenue 100.0% 100.0% 100.0% 100.0% 19.4% 142.0% 168.8%
Returns
Return on capital โ€” โˆ’465.9% โ€” โ€” โ€” โ€” โ€”
Return on capital employed โˆ’304.8% โˆ’29.6% โˆ’52.3% โˆ’220.8% โˆ’86.4% โˆ’164.5% โˆ’35.1%
Return on equity โ€” โˆ’624.2% โˆ’55.2% โˆ’113.8% โˆ’156.5% โˆ’194.6% โˆ’52.1%
Return on assets โˆ’206.4% โˆ’71.9% โˆ’48.2% โˆ’90.0% โˆ’123.8% โˆ’150.7% โˆ’46.0%
Return on tangible equity โ€” โˆ’43.1% โˆ’51.3% โˆ’225.3% โˆ’89.1% โˆ’161.7% โˆ’33.5%
Growth
Revenue growth โ€” โ€” โ€” โ€” 280,260.0% โˆ’35.5% โˆ’23.2%
Share count change โ€” 209.8% 240.4% 5.1% 63.6% 195.5% 49.0%
Financial health
Debt / equity โ€” 0.0x โ€” โ€” โ€” โ€” โ€”
Interest coverage โˆ’225.0x โˆ’583.9x โ€” โ€” โ€” โ€” โ€”
Current ratio 1.9x 14.1x 5.8x 3.1x 6.6x 4.1x 14.7x
Quick ratio 1.9x 14.1x 5.8x 3.1x 6.6x 4.1x 14.7x
Capital allocation
Capex / revenue โˆ’242.7% โˆ’1,542.1% โˆ’790.0% 4,960.0% 5.9% 79.3% 139.5%
Stock comp / revenue โˆ’14.6% โˆ’1,634.2% โˆ’34,480.0% 106,640.0% 44.4% 174.2% 370.1%
Quality scores
Piotroski F-score โ€” 4.0 2.0 2.0 4.0 1.0 3.0
Altman Z'' โˆ’56.2 13.7 3.1 โˆ’19.5 โˆ’0.0 โˆ’7.8 13.9
Accruals ratio โˆ’16.7% โˆ’23.0% โˆ’12.7% โˆ’20.0% โˆ’115.0% โˆ’93.7% โˆ’4.7%

Source: SEC EDGAR XBRL filings (CIK 0001472012). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open